合成5'-甲基西奥协型素:疟疾腺氨酸脱氨酶的特定抑制剂
Peter C Tyler1, Erika A Taylor, Richard F G Fröhlich
1Carbohydrate Chemistry Team, Industrial Research Ltd., Lower Hutt, New Zealand. p.tyler@irl.cri.nz
Journal of the American Chemical Society
|May 10, 2007
概括
新的过渡状态模拟抑制剂专门针对Plasmodium falciparum腺脱氨酶 (PfADA),提供一种潜在的抗疟疾治疗,而不会损害人类细胞. 这些强有力的抑制剂对疟疾治疗有前途.
科学领域:
- 生物化学 生物化学
- 酶动力学 酶动力学
- 药品化学 药品化学 是一个
背景情况:
- 酶率加速与过渡状态稳定有关.
- 过渡状态模拟抑制剂与酶密切结合.
- 腺脱氨酶 (ADA) 是 purin代谢中的关键酶.
研究的目的:
- 设计和合成针对Plasmodium falciparum ADA (PfADA) 的特定过渡状态模拟抑制剂.
- 评估新型化合物对PfADA的抑制潜力,并将其与人类和牛的ADA进行比较.
- 探索PfADA特异性抑制剂作为抗疟疾药物的治疗潜力.
主要方法:
- 合成5'-甲基提奥科法米辛和5'-甲基提奥-2'-脱氧科法米辛作为过渡状态模仿剂.
- 酶抑制试验用于确定PfADA,人类ADA (HsADA) 和牛ADA (BtADA) 的解离常数 (Kd).
- 通过评估宿主酶的抑制来评估寄生虫特异性的评估.
主要成果:
- 合成的类似物强烈抑制了PfADA,其解离常数在皮科莫尔范围 (430和790 pM).
- 这些化合物没有对HsADA和BtADA进行可检测的抑制,显示出高特异性.
- 利用PfADA独特的基质特异性来实现寄生虫特异性抑制.
结论:
- 5'-甲基化菌素和5'-甲基-2'-脱氧化菌素是Plasmodium falciparum ADA的强效和特异性抑制剂.
- 这些抑制剂代表了开发新型抗疟疾药物的有希望的线索,这些药物准了寄生虫的纯素救援途径.
- 寄生虫特异性ADA抑制剂的开发可能会规避与抑制人类ADA相关的毒性.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:24Antiasthma Drugs: Methylxanthines
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...